Giannoula Klement of Sunnybrook and Women's College Health Sciences Center in Ontario, Canada reported that the current way of administering chemotherapy may not take full advantage of the drugs' ability to attack the blood vessel formation of tumors (angiogenesis). Klement believes that the best way to inhibit angiogenesis is to administer lower doses of chemotherapy drugs on a more frequent basis-without periods of rest and for longer periods of time. This new treatment regimen is called "antiangiogenic scheduling" or "metronomic dosing." Klement believes that this new approach is promising, especially if angiogenesis-inhibiting drugs are added to the chemotherapy mix (combination chemotherapy). However, there is still skepticism among researchers as to the validity of Klement's conclusions, especially given the lack of available evidence from human clinical trials. Klement noted that a clinical trial is ongoing at the Hospital for Sick Children in Toronto to study the effect of metronomic chemotherapy in combination with cyclo-oxygenase 2 inhibitors to measure any improved efficacy against tumor blood vessel formation. SOURCE: 2nd International Conference on Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention, June 2-6, 2001, North Falmouth, Massachusetts As reported by Artemis, journal from Johns Hopkins Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.